Evaluating Vicagrel for patients with Acute Coronary Syndrome undergoing heart procedures
Official title: Efficacy and Safety of Vicagrel in Patients With With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI): a Multi-center, Randomized, Double-blind, Double-dummy , Parallel-controlled, Phase III Trial
Run by Jiangsu vcare pharmaceutical technology co., LTD · NCT06577519 · Data updated 2026-11-12
This study is testing if a new medication called Vicagrel can help people with Acute Coronary Syndrome who are having heart procedures feel better and stay safe compared to a standard treatment.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Jiangsu vcare pharmaceutical technology co., LTD Industry-sponsored |
| Locations | 1 site (Shenyang, Liaoning) |
| Status | Recruiting |
| Started | September 6, 2024 |
| Main results expected | December 30, 2026 |
| Study ends | December 30, 2026 |
| Registry record updated | July 27, 2026 |
| Trial ID | NCT06577519 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 to 80 who have been diagnosed with Acute Coronary Syndrome and are scheduled for a Percutaneous Coronary Intervention.
✕Probably not a fit
Patients with a life expectancy of less than 12 months or those with severe liver dysfunction may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase III clinical trial is a multi-center, randomized, double-blind, double-dummy, parallel-controlled study designed to assess the efficacy and safety of Vicagrel capsules in patients diagnosed with Acute Coronary Syndrome (ACS) who are scheduled for Percutaneous Coronary Intervention (PCI). Participants will receive either Vicagrel or Clopidogrel as part of their treatment regimen. The study aims to determine the long-term benefits of Vicagrel in this patient population, focusing on both effectiveness and safety outcomes.
Why it matters
Potential benefit: If successful, this study could provide a new treatment option that improves outcomes for patients with Acute Coronary Syndrome undergoing PCI.
How similar studies have gone: Other studies have shown success with similar approaches in evaluating antiplatelet therapies in ACS patients, indicating that this area of research is both relevant and promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients between 18 and 80 years old, with no gender restrictions. * Patients diagnosed with ACS and scheduled for PCI, including STEMI and NSTE-ACS (UA/NSTEMI). * Voluntarily sign the ICF and be able to follow the visit arrangements specified in the protocol during the trial period. Exclusion Criteria: * Expected survival time\<12 months; * Severe liver dysfunction (non heart disease induced ALT or AST\>3x ULN) and cirrhosis; * Pregnant or lactating women, or participants and their partners who plan to become pregnant during the trial period; * The researchers determined that other reasons were not suitable for participants in this experiment.
Where it's running
-
General Hospital of Northern Theater Command of Chinese PLA
Shenyang, Liaoning, China Recruiting
Study contacts
- Study coordinator: Xiaojuan Lai
- Email: lai_xiaojuan@vcarepharmatech.com
- Phone: 15358160458
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Rapid guideline-based therapy after a heart attack
This project tests whether starting guideline-driven secondary prevention soon after a heart attack helps people who had PCI reach better risk-factor control and fewer heart events.
-
Drug-coated balloon treatment during emergency angioplasty for STEMI
This registry will try using drug-coated balloons instead of stents during emergency PCI for people with ST-elevation heart attacks to see how the procedure and patient outcomes compare.
-
AI detection of hidden coronary occlusions and timing of treatment for heart attacks
This project tests whether an AI reading of 12‑lead ECGs can find hidden coronary occlusions in adults with suspected non‑ST‑elevation ACS and whether the time to PCI after that detection relates to troponin peak levels.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.